Just how close are we to a cure for Alzheimer’s? During this interactive webinar, our experts Mikey Hoag, Founder of Part the Cloud and Heather Snyder, Ph.D., Vice President of Medical and Scientific Relations at the Alzheimer’s Association give you an inside look at the latest and greatest research projects that are in development in the race to end Alzheimer’s.
Listen in as they discuss their partnership over the last decade to fuel high risk, high reward Alzheimer’s research. Founded in 2012, Part the Cloud funds research grants that are specifically intended to move treatments through early phase clinical trials in humans. In just ten years, Part the Cloud has raised more than $65 million and currently funds 65 human trials across the globe. These projects have gone on to receive more than $1 billion in additional funding from other sources.
Mikey Hoag is the Founder of Part the Cloud, the highly successful Alzheimer’s research fundraiser that takes place in Silicon Valley every year. After losing her father to early-onset Alzheimer’s, Mikey Hoag founded Part the Cloud in 2012 with the goal to educate, fundraise and to accelerate critically needed Alzheimer’s disease research. She realized that her personal story could have the power to rally people around the Alzheimer’s cause, so she partnered with the Alzheimer’s Association and a steering committee of women affected by the disease to launch the first Part the Cloud Gala
Heather M. Snyder, Ph.D., is Vice President, Medical & Scientific Relations at the Alzheimer’s Association. Dr. Snyder oversees the Association’s funding mechanisms; as the world’s largest nonprofit funder of Alzheimer’s research, the Association is currently investing $310 million in more than 950 active best-of-field projects in 48 countries. She is on the executive team for the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER). She also serves on the study team for the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), a tool that will collect longitudinal diagnostic and therapeutic clinical data, including measures of cognition, function and safety, from individuals treated with FDA-approved Alzheimer’s therapies in clinical settings nationwide.